Página 2 - Melhores Biópsia médicos em Israel - TOP-40 médicos

Dr. Boaz Liberman, MD, is an orthopedic oncologist and sarcoma surgeon for adults and children. He directs the Orthopedic Oncology Unit and serves as Vice Head of Orthopedic Surgery at Sheba Medical Center. His focus is limb-sparing cancer surgery with functional reconstruction. He performs complex joint reconstruction, revision arthroplasty, MRgFUS, and reconstruction after bone metastases.

Education and training: MD, Tel Aviv University. Orthopedic surgery residency, Sheba Medical Center. Fellowships in Adult Reconstruction at Mount Sinai Hospital, Toronto, and in Orthopedic Oncology at Mount Sinai Hospital and Princess Margaret Cancer Centre. He is board-certified in Orthopedic Surgery and in Orthopedic Oncology Surgery. He is a Clinical Instructor at Tel Aviv University. Memberships include the Israel Medical Association, Israel Orthopedic Association, AATB, and EATB. He also serves on national advisory committees. His research covers bone and soft tissue sarcomas, serum markers, imaging-guided therapies, MRI arthrography, and the biomechanics of bone treated with MRgFUS.

O médico é um especialista altamente qualificado em Oncologia Pediátrica e Hemato-Oncologia no Centro Médico Hadassah, reconhecido na lista da Forbes dos melhores médicos em Israel de 2019-2020. Com mais de vinte anos de especialização em pediatria, hemato-oncologia pediátrica e transplante de medula óssea haploidêntico, o médico é uma figura proeminente no campo.<\/p>

O médico é graduado pela Universidade de Tel Aviv e está ativamente envolvido em associações profissionais, incluindo a Sociedade Israelense de Hematologia e Oncologia Pediátrica, a Associação Israelense de Câncer, a Associação Internacional de Oncologia e a Sociedade Internacional de Oncologia Pediátrica. Os principais campos de interesse incluem retinoblastoma, medicina de precisão e oncologia pediátrica.<\/p>

O médico é um oncocirurgião distinto com ampla experiência em urologia. Especializando-se em técnicas cirúrgicas avançadas, o médico contribuiu significativamente para o campo da oncologia urológica. Com foco em procedimentos minimamente invasivos, o médico realizou com sucesso inúmeras cirurgias complexas, melhorando os resultados dos pacientes. O médico também está ativamente envolvido em pesquisa clínica, contribuindo para várias publicações revisadas por pares e apresentando descobertas em conferências internacionais.<\/p>

O médico é um especialista em radioterapia e oncologista altamente qualificado com ampla experiência no tratamento de vários tipos de câncer. Especializando-se em técnicas avançadas de radioterapia, o médico contribuiu significativamente para melhorar os resultados dos pacientes através de planos de tratamento inovadores. O médico é acreditado por conselhos médicos líderes e publicou numerosos artigos de pesquisa em revistas médicas de prestígio, enriquecendo o campo da oncologia com descobertas inovadoras.<\/p>

O médico é um oncocirurgião altamente experiente, com foco em técnicas cirúrgicas avançadas para o tratamento do câncer. Com ampla experiência na área, o médico contribuiu significativamente para o desenvolvimento de protocolos cirúrgicos inovadores destinados a melhorar os resultados dos pacientes. O médico é reconhecido por sua dedicação à excelência clínica e publicou numerosos artigos de pesquisa em revistas médicas de prestígio. Como professor, o médico está ativamente envolvido na educação da próxima geração de cirurgiões, enfatizando a importância da precisão e do cuidado centrado no paciente na oncocirurgia.<\/p>

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Prof. Gil Raviv, MD, PhD, is Director of the Andrology Unit at Sheba Medical Center. He was listed among the Best Doctors in Israel by Forbes in 2024. He is a leading expert in male fertility, sexual medicine, and reconstructive urology.

His primary focus is male infertility and fertility preservation. He performs advanced semen analysis according to WHO standards. He carries out testicular sperm retrieval (TESE, TESA, MESA) and semen cryopreservation. He also provides comprehensive fertility diagnostics with histological analysis.

He is a Professor at Tel Aviv University. He trained in Siena, Rome, and Tel Aviv. He completed a fellowship in infertility and impotence at Erasme Hospital. He received advanced training in reconstructive urethral surgery in Ghent. He is a member of the European Association of Urology, the International Society for Sexual Medicine, and the Israeli Urological Association.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

O médico é um mamologista altamente experiente, especializado em cirurgia mamária. Com foco em técnicas cirúrgicas inovadoras, o médico lidera o Departamento de Cirurgia Mamária, garantindo cuidados e resultados de primeira linha para os pacientes. O médico é reconhecido por suas contribuições para o tratamento do câncer de mama e publicou numerosos artigos de pesquisa em revistas médicas de prestígio. O médico também está envolvido em ensaios clínicos destinados a melhorar as terapias para o câncer de mama e recebeu múltiplos prêmios por excelência na prática cirúrgica e no cuidado ao paciente.<\/p>

O médico é ginecologista especializado em operações endoscópicas e laparoscópicas. Com foco em técnicas cirúrgicas minimamente invasivas, o médico é habilidoso em realizar procedimentos avançados que melhoram a recuperação e os resultados dos pacientes. O médico tem ampla experiência no manejo de casos ginecológicos complexos, utilizando tecnologia de ponta para fornecer cuidados ótimos.<\/p>

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.